Intravenous immunoglobulin for treatment of mild-to-moderate Alzheimer's disease: a phase 2, randomised, double-blind, placebo-controlled, dose-finding trial-Reference-Cited by-同舟云学术

Intravenous immunoglobulin for treatment of mild-to-moderate Alzheimer's disease: a phase 2, randomised, double-blind, placebo-controlled, dose-finding trial

Published:2013-03 Issue:3 Volume:12 Page:233-243
ISSN:1474-4422
Container-title:The Lancet Neurology
language:en
Short-container-title:The Lancet Neurology

Author:

Dodel Richard,Rominger Axel,Bartenstein Peter,Barkhof Frederik,Blennow Kaj,Förster Stefan,Winter Yaroslav,Bach Jan-Philipp,Popp Julius,Alferink Judith,Wiltfang Jens,Buerger Katharina,Otto Markus,Antuono Piero,Jacoby Michael,Richter Ralph,Stevens James,Melamed Isaac,Goldstein Jerome,Haag Stefan,Wietek Stefan,Farlow Martin,Jessen Frank

Publisher

Elsevier BV

Subject

Clinical Neurology

Reference32 articles.

1. Alzheimer's disease: clinical trials and drug development;Mangialasche;Lancet Neurol,2010

2. Intravenous immunoglobulins containing antibodies against beta-amyloid for the treatment of Alzheimer's disease;Dodel;J Neurol Neurosurg Psychiatry,2004

3. Reduced levels of amyloid beta-peptide antibody in Alzheimer disease;Du;Neurology,2001

4. Current state of immunotherapy for Alzheimer's disease;Relkin;CNS Spectr,2008

5. 18-month study of intravenous immunoglobulin for treatment of mild Alzheimer disease;Relkin;Neurobiol Aging,2009

Cited by 171 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Engineered Antibodies to Improve Efficacy against Neurodegenerative Disorders;International Journal of Molecular Sciences;2024-06-18

2. Neuroinflammation in Alzheimer’s disease: insights from peripheral immune cells;Immunity & Ageing;2024-06-14

3. Blood-based therapies to combat neurodegenerative diseases;Metabolic Brain Disease;2024-06-06

4. From Longitudinal Measurements to Image Classification: Application to Longitudinal MRI in Alzheimer’s Disease;Lecture Notes in Networks and Systems;2024

5. Antibody-Mediated Clearance of Brain Amyloid-β: Mechanisms of Action, Effects of Natural and Monoclonal Anti-Aβ Antibodies, and Downstream Effects;Journal of Alzheimer's Disease Reports;2023-08-14